BCBS Alabama · Heart Disease Risk Reduction

BCBS Alabama coverage for Wegovy (Heart Disease Risk Reduction)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 45 and older
BMI of 27 or higher
Established cardiovascular disease (CV death (qualifying history), non-fatal MI, and non-fatal stroke)
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV risk reduction in adults with established CVD and overweight/obesity without diabetes

All of:

Age >= 45 years
Established cardiovascular disease
BMI >= 27 kg/m2
No diabetes diagnosis (SELECT trial enrolled patients without diabetes)

Plus any one of:

History of non-fatal MI
History of non-fatal stroke
Other established CV disease

Documentation to bring

Documentation of established cardiovascular disease (CV death history, non-fatal MI, non-fatal stroke, or equivalent)
Baseline BMI documentation >= 27 kg/m2
Confirmation of absence of diabetes diagnosis
Age >= 45 years confirmed

Not covered when

Patients WITH diabetes were excluded from the SELECT trial; CV indication inferred for non-diabetic patients only
Concomitant use with other semaglutide-containing products not recommended
Concomitant use with any other GLP-1 receptor agonist not recommended
Pregnancy

Policy note: CV risk reduction indication supported by SELECT trial data (NCT03574597): semaglutide 2.4 mg reduced MACE by 20% vs placebo in patients >= 45 years with BMI >= 27 and established CVD WITHOUT diabetes. The policy document references this trial to support the indication. Age minimum of 45 is derived from SELECT trial enrollment criteria referenced in the document. The FDA label indication is for adults with established CV disease and obesity or overweight, but the document specifically references the non-diabetic population from SELECT.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ALBP_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace